Company intelligence / Profile preview
Spyre Therapeutics, Inc.
Waltham, Massachusetts, United States of Americaspyre.com ↗
- Ownership
- Public · SYRE
- Employees
- ~65
- Development stage
- Other
01
Overview
SPY001 (α4β7) showed favorable safety profile in Phase 1 with half-life estimates >90 days supporting potential Q6M maintenance dosing. Phase 2 trial in UC planned for mid-2025. Interim Phase 1 data readouts for SPY002 and SPY003 expected in Q2 and H2 2025, respectively.
- Therapeutic areas
- GastroenterologyRheumatology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Paragon Therapeutics
04
Financials
- Market cap
- $8.9B
- Total revenue
- $0
- Enterprise value
- $7.8B
Beyond the preview
Go deeper on Spyre Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spyre Therapeutics, Inc..